Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CERENOME, INC.CTYX · Entity 7637 | Director | January 26, 2017 | January 27, 2017 |
| Jasper Therapeutics, Inc.JSPR · Entity 7588 | Director · President, CEO and Director | January 02, 2026 | January 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CERENOME, INC.
Report date January 26, 2017 · Filed January 27, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.56 · Expires 2027-01-26 | Direct | 50,000 |
Reported balance
After 2017-01-26 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-01-26 · Grant · Acquired 50,000 · Balance 50,000 F1: The reporting person received a non-qualified stock option granted under the Issuer's 2014 Equity Incentive Plan. The exercise price per share to be paid by the reporting person at the time the option is exercised is the closing sale price of the Issuer's Common Stock on the NASDAQ Stock Market as of the date of the grant. The closing sale price on the date of the grant was $1.56. F2: Fifty percent (50%) of the option shares shall vest on January 26, 2018 with the remaining fifty percent (50%) of the option shares vesting on January 26, 2019. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting person received a non-qualified stock option granted under the Issuer's 2014 Equity Incentive Plan. The exercise price per share to be paid by the reporting person at the time the option is exercised is the closing sale price of the Issuer's Common Stock on the NASDAQ Stock Market as of the date of the grant. The closing sale price on the date of the grant was $1.56.
F2: Fifty percent (50%) of the option shares shall vest on January 26, 2018 with the remaining fifty percent (50%) of the option shares vesting on January 26, 2019.
Jasper Therapeutics, Inc.
Report date January 02, 2026 · Filed January 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.84 · Expires 2036-01-02 | Direct | 234,000 |
Reported balance
After 2026-01-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-02 · Grant · Acquired 234,000 · Balance 234,000 F1: 1/4th of the shares subject to the option shall vest on January 2, 2027, and 1/48th of the original number of shares subject to the option shall vest following each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive. |
Filing footnotes · ownership attribution and instrument terms
F1: 1/4th of the shares subject to the option shall vest on January 2, 2027, and 1/48th of the original number of shares subject to the option shall vest following each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 02, 2026 Filed Jan 5, 2026 19:30 UTC | Jasper Therapeutics, Inc. JSPR · Entity 7588 | GrantStock Option (right to buy) · Derivative | 234,000 | $0.00 Strike: $1.84 | $0.00 |
DisclosureSEC source: 0001213900-26-001385 · ownership.xml · derivative · entry 1 MARTELL RON · CIK 0001177079 · Director · President, CEO and Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 234,000 Underlying: Voting Common Stock · 234,000 shares Expires 2036-01-02 F1 · derivative.exercise_date: 1/4th of the shares subject to the option shall vest on January 2, 2027, and 1/48th of the original number of shares subject to the option shall vest following each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive. Read SEC document |
| September 22, 2025 Filed Sep 24, 2025 16:01 UTC | Jasper Therapeutics, Inc. JSPR · Entity 7588 | PurchaseCommon Stock Warrant (right to buy) · Derivative | 41,000 | Not disclosed Strike: $2.92 | Not disclosed |
DisclosureSEC source: 0001213900-25-091099 · ownership.xml · derivative · entry 2 MARTELL RON · CIK 0001177079 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,000 Underlying: Voting Common Stock · 41,000 shares Expires 2030-03-22 F1 · price: Each share of voting common stock was purchased together with an accompanying warrant to purchase one share of voting common stock in an underwritten public offering at a combined offering price of $2.43 per share of voting common stock and accompanying warrant. Read SEC document |
| September 22, 2025 Filed Sep 24, 2025 16:01 UTC | Jasper Therapeutics, Inc. JSPR · Entity 7588 | PurchaseVoting Common Stock | 41,000 | $2.43 | $99,630.00 |
DisclosureSEC source: 0001213900-25-091099 · ownership.xml · nonDerivative · entry 1 MARTELL RON · CIK 0001177079 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,118 F1 · price: Each share of voting common stock was purchased together with an accompanying warrant to purchase one share of voting common stock in an underwritten public offering at a combined offering price of $2.43 per share of voting common stock and accompanying warrant. Read SEC document |
| June 04, 2025 Filed Jun 6, 2025 06:30 UTC | Jasper Therapeutics, Inc. JSPR · Entity 7588 | GrantStock Option (right to buy) · Derivative | 234,000 | $0.00 Strike: $6.00 | $0.00 |
DisclosureSEC source: 0001213900-25-051729 · ownership.xml · derivative · entry 1 MARTELL RON · CIK 0001177079 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 234,000 Underlying: Voting Common Stock · 234,000 shares Expires 2035-06-04 F1 · derivative.exercise_date: 1/4th of the shares subject to the retention option shall vest on June 4, 2026 and 1/48th of the shares subject to the retention option shall vest following each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive. Read SEC document |
| February 13, 2025 Filed Feb 18, 2025 17:30 UTC | Jasper Therapeutics, Inc. JSPR · Entity 7588 | GrantStock Option (right to buy) · Derivative | 130,000 | $0.00 Strike: $6.20 | $0.00 |
DisclosureSEC source: 0001213900-25-014950 · ownership.xml · derivative · entry 1 MARTELL RON · CIK 0001177079 · Director · President, CEO and Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 130,000 Underlying: Voting Common Stock · 130,000 shares Expires 2035-02-13 F1 · derivative.exercise_date: 1/4th of the shares subject to the option shall vest on February 13, 2026, and 1/48th of the original number of shares subject to the option shall vest following each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive. Read SEC document |
| June 10, 2024 Filed Jun 12, 2024 16:09 UTC | Jasper Therapeutics, Inc. JSPR · Entity 7588 | GrantPerformance Restricted Stock Units · Derivative | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-24-052087 · ownership.xml · derivative · entry 2 MARTELL RON · CIK 0001177079 · Director · President, CEO and Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Voting Common Stock · 20,000 shares Expires 2026-06-10 F2 · derivative.exercise_price: Represents a grant of performance-based restricted stock units ("PRSUs"), with each PRSU representing a contingent right to receive one share of common stock of the Issuer. F3 · derivative.exercise_date: If, by June 10, 2026, the closing price of the Issuer's common stock on the Nasdaq Capital Market is at or above $35.00 per share (subject to adjustment for recapitalizations, stock splits and similar transactions) for thirty consecutive calendar days, all of the shares of the Issuer's common stock subject to the PRSUs shall vest in full on such thirtieth day, so long as the Reporting Person provides continuous services to the Issuer on and through the vesting date, inclusive. Read SEC document |
| June 10, 2024 Filed Jun 12, 2024 16:09 UTC | Jasper Therapeutics, Inc. JSPR · Entity 7588 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $23.95 | $0.00 |
DisclosureSEC source: 0001213900-24-052087 · ownership.xml · derivative · entry 1 MARTELL RON · CIK 0001177079 · Director · President, CEO and Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Voting Common Stock · 10,000 shares Expires 2034-06-10 F1 · derivative.exercise_date: 1/4th of the shares subject to the option shall vest on June 10, 2025, and 1/48th of the shares subject to the option shall vest following each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive. Read SEC document |
| February 15, 2024 Filed Feb 20, 2024 19:33 UTC | Jasper Therapeutics, Inc. JSPR · Entity 7588 | GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $17.95 | $0.00 |
DisclosureSEC source: 0001213900-24-015465 · ownership.xml · derivative · entry 1 MARTELL RON · CIK 0001177079 · Director · President, CEO and Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Voting Common Stock · 100,000 shares Expires 2034-02-15 F1 · derivative.exercise_date: 1/4th of the shares subject to the option shall vest on February 15, 2025, and 1/48th of the shares subject to the option shall vest following each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive. Read SEC document |
| October 12, 2023 Filed Oct 13, 2023 18:57 UTC | Jasper Therapeutics, Inc. JSPR · Entity 7588 | Tax withholdingVoting Common Stock | 87,531 | $0.85 | $74,401.35 |
DisclosureSEC source: 0001013762-23-003902 · ownership.xml · nonDerivative · entry 1 MARTELL RON · CIK 0001177079 · Director · President, CEO & Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 331,188 F1 · shares: These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares of the Issuer's common stock upon the vesting of restricted stock units. Read SEC document |
| April 12, 2023 Filed Apr 14, 2023 16:17 UTC | Jasper Therapeutics, Inc. JSPR · Entity 7588 | Tax withholdingVoting Common Stock | 87,531 | $1.46 | $127,795.26 |
DisclosureSEC source: 0001213900-23-029896 · ownership.xml · nonDerivative · entry 1 MARTELL RON · CIK 0001177079 · Director · President, CEO and Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 418,719 F1 · shares: These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares of the Issuer's common stock upon the vesting of restricted stock units. Read SEC document |
| March 17, 2023 Filed Mar 20, 2023 17:59 UTC | Jasper Therapeutics, Inc. JSPR · Entity 7588 | GrantStock Option (right to buy) · Derivative | 500,000 | $0.00 Strike: $1.87 | $0.00 |
DisclosureSEC source: 0001213900-23-021493 · marketforms-60958.xml · derivative · entry 1 MARTELL RON · CIK 0001177079 · Director · President, CEO and Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 500,000 Underlying: Voting Common Stock · 500,000 shares Expires 2033-03-17 F1 · derivative.exercise_date: 1/4th of the shares subject to the option shall vest on March 3, 2024, and 1/48th of the shares subject to the option shall vest following each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive. Read SEC document |
| February 02, 2023 Filed Feb 3, 2023 16:13 UTC | Jasper Therapeutics, Inc. JSPR · Entity 7588 | GrantStock Option (right to buy) · Derivative | 1,093,831 | $0.00 Strike: $1.78 | $0.00 |
DisclosureSEC source: 0001213900-23-007992 · ownership.xml · derivative · entry 1 MARTELL RON · CIK 0001177079 · Director · President, CEO & Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,093,831 Underlying: Voting Common Stock · 1,093,831 shares Expires 2033-02-02 F1 · derivative.exercise_date: 1/4th of the shares subject to the option shall vest on February 2, 2024, and 1/48th of the shares subject to the option shall vest following each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive. Read SEC document |
| October 12, 2022 Filed Oct 13, 2022 20:08 UTC | Jasper Therapeutics, Inc. JSPR · Entity 7588 | GrantVoting Common Stock | 506,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-22-063949 · ownership.xml · nonDerivative · entry 1 MARTELL RON · CIK 0001177079 · Director · President, CEO and Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 506,250 F1 · shares: The reported securities are represented by restricted stock units, 1/2 of which shall vest on each of April 12, 2023 and October 12, 2023, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive. Read SEC document |
| March 21, 2022 Filed Mar 23, 2022 18:06 UTC | Jasper Therapeutics, Inc. JSPR · Entity 7588 | GrantStock Option (right to buy) · Derivative | 1,704,328 | $0.00 Strike: $3.54 | $0.00 |
DisclosureSEC source: 0001213900-22-014572 · ownership.xml · derivative · entry 1 MARTELL RON · CIK 0001177079 · Director · President, CEO and Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,704,328 Underlying: Common Stock · 1,704,328 shares Expires 2032-03-21 F1 · derivative.exercise_date: 1/4th of the shares subject to the option shall vest on March 15, 2023, and 1/48th of the shares subject to the option shall vest following each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive. Read SEC document |
| January 26, 2017 Filed Jan 27, 2017 22:46 UTC | CERENOME, INC. CTYX · Entity 7637 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $1.56 | $0.00 |
DisclosureSEC source: 0001209191-17-005970 · doc4.xml · derivative · entry 1 MARTELL RON · CIK 0001177079 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2027-01-26 F1 · derivative.exercise_price: The reporting person received a non-qualified stock option granted under the Issuer's 2014 Equity Incentive Plan. The exercise price per share to be paid by the reporting person at the time the option is exercised is the closing sale price of the Issuer's Common Stock on the NASDAQ Stock Market as of the date of the grant. The closing sale price on the date of the grant was $1.56. F2 · derivative.exercise_date: Fifty percent (50%) of the option shares shall vest on January 26, 2018 with the remaining fifty percent (50%) of the option shares vesting on January 26, 2019. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.